Scpharmaceuticals (NASDAQ:SCPH) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Scpharmaceuticals (NASDAQ:SCPH) posted its quarterly earnings data on Wednesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.10, Bloomberg Earnings reports.

Shares of NASDAQ:SCPH traded up $0.03 on Friday, hitting $5.70. 9,766 shares of the company were exchanged, compared to its average volume of 86,601. The firm’s 50 day moving average price is $4.37. Scpharmaceuticals has a one year low of $2.44 and a one year high of $6.40. The company has a debt-to-equity ratio of 0.10, a current ratio of 8.50 and a quick ratio of 8.50. The stock has a market capitalization of $111.85 million, a price-to-earnings ratio of -3.58 and a beta of 0.94.

SCPH has been the topic of several research reports. ValuEngine downgraded shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research upgraded shares of Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Saturday.

About Scpharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Recommended Story: What is Forex?

Earnings History for Scpharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with's FREE daily email newsletter.